Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11
ConclusionThese data suggest that the OIS regimen is effective and relatively well tolerated in patients with advanced gastric cancer. Given that all the patients treated, but one, had a good performance status, these results must be confirmed in a patient population more representative of regular clinical practice.Trial RegistrationClinicalTrials.gov Identifier: NCT02527785.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Pain | Study | Toxicology